Deep-pocketed investors have adopted a bullish approach towards AbbVie (NYSE:ABBV), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in ABBV usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 8 extraordinary options activities for AbbVie. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 62% leaning bullish and 25% bearish. Among these notable options, 3 are puts, totaling $513,300, and 5 are calls, amounting to $229,374.
Expected Price Movements
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $150.0 to $210.0 for AbbVie over the recent three months.
Analyzing Volume & Open Interest
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for AbbVie's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of AbbVie's whale activity within a strike price range from $150.0 to $210.0 in the last 30 days.
AbbVie Option Volume And Open Interest Over Last 30 Days
Noteworthy Options Activity:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ABBV | PUT | TRADE | NEUTRAL | 12/19/25 | $22.15 | $21.7 | $21.9 | $200.00 | $438.0K | 236 | 200 |
| ABBV | CALL | SWEEP | BEARISH | 11/15/24 | $2.75 | $2.74 | $2.75 | $210.00 | $52.0K | 1.6K | 199 |
| ABBV | CALL | TRADE | BULLISH | 01/17/25 | $18.15 | $17.9 | $18.1 | $185.00 | $50.6K | 3.7K | 31 |
| ABBV | CALL | TRADE | BULLISH | 09/20/24 | $16.9 | $16.55 | $16.9 | $180.00 | $47.3K | 4.3K | 40 |
| ABBV | PUT | TRADE | BULLISH | 01/16/26 | $6.45 | $6.2 | $6.2 | $150.00 | $46.5K | 338 | 77 |
About AbbVie
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
After a thorough review of the options trading surrounding AbbVie, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
AbbVie's Current Market Status
- With a volume of 3,466,441, the price of ABBV is up 1.56% at $196.42.
- RSI indicators hint that the underlying stock may be approaching overbought.
- Next earnings are expected to be released in 46 days.
Professional Analyst Ratings for AbbVie
2 market experts have recently issued ratings for this stock, with a consensus target price of $213.5.
- Consistent in their evaluation, an analyst from Morgan Stanley keeps a Overweight rating on AbbVie with a target price of $218.
- Consistent in their evaluation, an analyst from Piper Sandler keeps a Overweight rating on AbbVie with a target price of $209.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest AbbVie options trades with real-time alerts from Benzinga Pro.
